Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our Dark Pool Levels

AVDL
Avadel Pharmaceuticals plc
stock NASDAQ

Market Open
Jun 11, 2025 9:47:02 AM EDT
10.23USD0.000%(0.00)100,121
10.15Bid   10.21Ask   0.06Spread
Pre-market
Jun 11, 2025 8:50:30 AM EDT
10.23USD0.000%(0.00)15,525
After-hours
Jun 10, 2025 4:00:30 PM EDT
10.23USD-0.098%(-0.01)0
OverviewOption ChainMax PainOptionsHistoricalExchange VolumeDark Pool LevelsDark Pool PrintsExchangesShort VolumeShort Interest - DailyShort InterestBorrow Fee (CTB)Failure to Deliver (FTD)ShortsTrendsNewsNews
Jan 11, 2022
06:28AM EST  Needham Maintains Buy on Avadel Pharmaceuticals, Lowers Price Target to $15   Benzinga
Nov 22, 2021
08:00AM EST  Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, announced today that Greg Divis, Chief Executive Officer of Avadel, will participate in the following upcoming investor conferences:   GlobeNewswire Inc
Nov 9, 2021
08:00AM EST  Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, announced today that Greg Divis, Chief Executive Officer of Avadel, will participate in the following upcoming investor conferences in November:   GlobeNewswire Inc
Nov 8, 2021
08:22AM EST  Avadel Pharmaceuticals Q3 EPS $(0.38), Inline   Benzinga
08:00AM EST  -- FDA review of NDA for FT218 ongoing; commercial and launch preparations progressing   GlobeNewswire Inc
05:06AM EST  Earnings Scheduled For November 8, 2021   Benzinga
Nov 1, 2021
04:37PM EDT  Pomerantz LLP is investigating claims on behalf of investors of Avadel Pharmaceuticals plc (Avadel or the Company) (NASDAQ:AVDL). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.   GlobeNewswire Inc
08:00AM EDT  Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, announced today that it will host a conference call and live webcast at 8:30 a.m. ET on Monday, November 8, 2021, to provide a corporate update and discuss the Company's financial results for the third quarter ended September 30, 2021.   GlobeNewswire Inc
Oct 19, 2021
08:22AM EDT  Avadel Pharma Highlights New Data On Once-At-Bedtime FT218, Preference For Once-Nightly Dosing In Patients With Narcolepsy At American College of Chest Physicians Meeting   Benzinga
08:00AM EDT  - Post-hoc responder analyses demonstrated a significantly greater proportion of patients receiving FT218 experienced reductions in weekly cataplexy attacks and improvement in mean sleep latency compared to placebo -   GlobeNewswire Inc
Oct 18, 2021
07:34AM EDT  The Week Ahead In Biotech (Oct. 18-23): J&J, Biogen Kickstart Big Pharma Earnings, Regeneron-Sanofi, Roche Await FDA Decisions And IPOs   Benzinga
06:44AM EDT  The following are some of the stocks making big moves in Monday's pre-market trading (as of 06.30 A.M. EDT).   RTTNews
Oct 15, 2021
10:18PM EDT  The U.S. Food and Drug Administration notified Avadel Pharmaceuticals plc (AVDL) that the review of the New Drug Application (NDA) for FT218 is still ongoing, and action will likely not be taken in October.   RTTNews
05:02PM EDT  Avadel Pharmaceuticals Announces Ongoing FDA Review Of NDA For FT218 For Patients With Narcolepsy   Benzinga
05:01PM EDT  Oyster Point PharmaAvadel Pharmaceuticals Announces Ongoing FDA Review Of NDA For FT218 For Patients With Narcolepsy   Benzinga
05:00PM EDT  Avadel Pharmaceuticals Announces Ongoing FDA Review of NDA for   GlobeNewswire Inc
08:05AM EDT  Ascendis Pharma Announces U.S. Commercial Launch Of SKYTROFA For Pediatric Growth Hormone Deficiency   RTTNews
07:44AM EDT  The Daily Biotech Pulse: Moderna's Booster Shot Gets FDA Panel Backing, Decision Day For Avadel, Silence Therapeutics Strikes Licensing Deal, MiNK IPO   Benzinga
05:44AM EDT  The following are some of the stocks making big moves in Friday's pre-market trading (as of 05.25 A.M. EDT).   RTTNews
Oct 11, 2021
08:59AM EDT  Benzinga Pro's Top 5 Stocks To Watch For Monday, Oct. 11, 2021: SOFI, PTGX, GTLB, PRPH, AVDL   Benzinga
06:08AM EDT  The following are some of the stocks making big moves in Monday's pre-market trading (as of 5.55 A.M. EDT).   RTTNews
Oct 10, 2021
11:59AM EDT  The Week Ahead In Biotech (Oct. 10-16): Avadel FDA Decision, Conference Presentations and IPOs Take Center Stage   Benzinga
Oct 5, 2021
08:01AM EDT  The Daily Biotech Pulse: J&J Files For Booster Dose Authorization, Gemini Restructures, Strata Skin CFO Departs, Kaleido Reports Positive Readout   Benzinga
Oct 4, 2021
10:14AM EDT  UPDATE: Needham On Avadel: Firm Believes Co. 'Has A High Likelihood Of Obtaining FDA Approval For FT218' & Highlights Additional Catalyst Of Winning Against Jazz On Their Motion For A Preliminary Injunction Order To Prevent Avadel From Launching   Benzinga
09:49AM EDT  Needham Maintains Buy Rating On Avadel Pharmaceuticals With $17 Price Target   Benzinga
Oct 1, 2021
02:29PM EDT  Attention Biotech Investors: Mark Your Calendar For October PDUFA Dates   Benzinga
Sep 29, 2021
08:13AM EDT  The Daily Biotech Pulse: AbbVie's Migraine Drug OK'd By FDA, Amicus Spins Off Gene Therapy Business, Geovax In-Licenses Cancer Drug   Benzinga
Sep 23, 2021
10:06AM EDT  Benzinga's Top Ratings Upgrades, Downgrades For September 23, 2021   Benzinga
04:48AM EDT  Needham Initiates Coverage On Avadel Pharmaceuticals with Buy Rating, Announces Price Target of $17   Benzinga
Sep 20, 2021
08:07AM EDT  Avadel Recognizes World Narcolepsy Day And Announces New Data Presentations From Pivotal Phase 3 REST-ON Trial Of FT218 At Upcoming Conference   Benzinga
08:00AM EDT  Avadel Recognizes World Narcolepsy Day and Announces New Data   GlobeNewswire Inc
Sep 2, 2021
08:00AM EDT  Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate for treating excessive daytime sleepiness and cataplexy in adults with narcolepsy, announced today that Greg Divis, Chief Executive Officer of Avadel, will participate in the following upcoming virtual investor conferences in September:   GlobeNewswire Inc
Aug 16, 2021
08:02AM EDT  Avadel Pharmaceuticals Announces Publication of Data from Pivotal Phase 3 REST-ON Trial of FT218 in Adults with Narcolepsy in SLEEP   Benzinga
08:00AM EDT  Avadel Pharmaceuticals Announces Publication of Data from Pivotal   GlobeNewswire Inc
Aug 9, 2021
11:07AM EDT  The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight   Benzinga
08:25AM EDT  Avadel Pharmaceuticals Q2 EPS $(0.33) Misses $(0.31) Estimate   Benzinga
08:00AM EDT  Avadel Pharmaceuticals Provides Corporate Update and Reports   GlobeNewswire Inc
04:11AM EDT  Earnings Scheduled For August 9, 2021   Benzinga
Aug 8, 2021
10:11AM EDT  The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight   Benzinga
Aug 2, 2021
08:00AM EDT  Avadel Pharmaceuticals to Provide a Corporate Update and Report   GlobeNewswire Inc
Jul 7, 2021
08:00AM EDT  Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate for treating excessive daytime sleepiness and cataplexy in adults with narcolepsy, announced today that Greg Divis, Chief Executive Officer of Avadel, will participate in a fireside chat on Wednesday, July 14 at 11:00 a.m. ET.   GlobeNewswire Inc
Jun 9, 2021
09:07AM EDT  Avadel Presents New Clinical Data From Pivotal Phase 3 REST-ON Trial Supporting Clinical Benefit Of FT218 In Patients With Narcolepsy At SLEEP 2021   Benzinga
09:00AM EDT  Avadel Presents New Clinical Data from Pivotal Phase 3 REST-ON   GlobeNewswire Inc
Jun 3, 2021
08:12AM EDT  Avadel To Present New Efficacy, Safety Data From Pivotal Phase 3 REST-ON Trial Of FT218 At SLEEP 2021   Benzinga
08:00AM EDT  Avadel to Present New Efficacy and Safety Data from Pivotal Phase   GlobeNewswire Inc
Jun 2, 2021
08:00AM EDT  Avadel Pharmaceuticals Expands Leadership Team with Three   GlobeNewswire Inc
May 25, 2021
08:00AM EDT  Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate for treating excessive daytime sleepiness and cataplexy in adults with narcolepsy, announced today that Greg Divis, Chief Executive Officer of Avadel, will participate in a fireside chat on Tuesday, June 1 at 9:00 a.m. ET.   GlobeNewswire Inc
May 10, 2021
08:49AM EDT  Avadel Pharmaceuticals Q1 EPS $(0.23) Beats $(0.32) Estimate   Benzinga
08:00AM EDT  -- Announced FDA acceptance of NDA for once-nightly FT218 and an October 15, 2021 target action PDUFA date -- Presented positive secondary endpoint data at the AAN 2021 Annual Meeting, which further highlights the overall clinical value proposition of FT218 -- FT218 launch preparation progressing -- Management to host a conference call today at 8:30 a.m. ET   GlobeNewswire Inc
04:09AM EDT  Earnings Scheduled For May 10, 2021   Benzinga
Apr 29, 2021
08:00AM EDT  Avadel Pharmaceuticals to Provide a Corporate Update and Report   GlobeNewswire Inc
Apr 19, 2021
07:05AM EDT  Avadel's Formulated Sodium Oxybate Shows Improved Sleepiness, Sleep Quality In Narcolepsy Patients   Benzinga
Apr 17, 2021
01:51PM EDT  Avadel Presents New Data From Pivotal REST-ON Phase 3 Trial Of FT218 AAN Meeting   RTTNews
08:00AM EDT  -- Secondary endpoint data for once-nightly FT218 further supports previously announced topline data demonstrating clinically meaningful results at 6 g, 7.5 g, and 9 g doses   GlobeNewswire Inc
Apr 8, 2021
08:04AM EDT  Avadel To Present New Data From Pivotal REST-ON Phase 3 Study Of FT218 At American Academy Of Neurology Annual Meeting 2021   Benzinga
08:00AM EDT  Avadel to Present New Data from its Pivotal REST-ON Phase 3 Study   GlobeNewswire Inc
Mar 18, 2021
08:01AM EDT  Avadel Pharmaceuticals to Participate in a Fireside Chat at   GlobeNewswire Inc
Mar 10, 2021
06:13AM EST  HC Wainwright & Co. Maintains Buy on Avadel Pharmaceuticals, Raises Price Target to $17   Benzinga
Mar 9, 2021
09:16AM EST  Avadel Pharmaceuticals Q4 EPS $(0.19) Beats $(0.27) Estimate   Benzinga
07:00AM EST  Avadel Pharmaceuticals Provides Corporate Update and Reports   GlobeNewswire Inc
04:09AM EST  Earnings Scheduled For March 9, 2021   Benzinga
Mar 6, 2021
10:58AM EST  The Week Ahead In Biotech (March 7-13): Conference Presentations And More Earnings   Benzinga
Mar 4, 2021
08:00AM EST  Avadel Pharmaceuticals and the American Academy of Sleep Medicine   GlobeNewswire Inc
Mar 2, 2021
08:11AM EST  Avadel Pharmaceuticals Highlights Publication Of Once-Nightly FT218 Pharmacokinetic Studies In Clinical Therapeutics Journal   Benzinga
08:00AM EST  Avadel Pharmaceuticals Announces Publication of Once-Nightly FT218   GlobeNewswire Inc
Mar 1, 2021
12:11PM EST  Avadel's US Application In Sleep Disorder Accepted For Review   Benzinga
08:04AM EST  Avadel Pharmaceuticals Announces FDA Acceptance Of New Drug Application For FT218 In Adults With Narcolepsy For Treatment Of Excessive Daytime Sleepiness And Cataplexy   Benzinga
08:00AM EST  Avadel Pharmaceuticals Announces FDA Acceptance of New Drug   GlobeNewswire Inc
Feb 25, 2021
08:00AM EST  Avadel Pharmaceuticals to Participate in Fireside Chats at   GlobeNewswire Inc
Feb 23, 2021
06:20PM EST  Avadel Pharmaceuticals to Provide a Company Update and Report   GlobeNewswire Inc
Feb 17, 2021
08:06AM EST  Avadel Pharmaceuticals Appoints Richard Kim As CCO; Says He Will Lead Launch Of Once-Nightly FT218, Pending Regulatory Approval   Benzinga
08:00AM EST  Avadel Pharmaceuticals Appoints Richard Kim as Chief Commercial   GlobeNewswire Inc
Feb 10, 2021
08:00AM EST  Avadel Pharmaceuticals to Participate in a Fireside   GlobeNewswire Inc
Dec 16, 2020
08:20AM EST  Avadel Announces Submission Of NDA To FDA For FT218   RTTNews
08:01AM EST  Avadel Pharmaceuticals Announces Submission Of New Drug Application For FT218 To FDA   Benzinga
08:00AM EST  Avadel Pharmaceuticals plc(Nasdaq: AVDL) today announced the submission of its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for FT218, an investigational, once-nightly formulation of sodium oxybate designed to treat excessive daytime sleepiness and cataplexy in adults with narcolepsy.   GlobeNewswire Inc
Dec 15, 2020
08:11AM EST  Avadel Pharma Reports Will Be Added To NASDAQ Biotech Index, Effective Monday, Dec. 21, 2020   Benzinga
08:00AM EST  Avadel Pharmaceuticals Added to NASDAQ Biotechnology Index   GlobeNewswire Inc
Dec 7, 2020
08:00AM EST  Avadel Pharmaceuticals Appoints Dr. Jennifer Gudeman as Vice   GlobeNewswire Inc
Nov 23, 2020
08:00AM EST  Avadel Pharmaceuticals to Present at Upcoming December 2020   GlobeNewswire Inc
Nov 19, 2020
02:58PM EST  Avadel Pharmaceuticals Option Alert: Dec 18 $7.5 Calls Sweep (21) near the Ask: 609 @ $0.5 vs 2057 OI; Ref=$6.7699   Benzinga
Nov 11, 2020
08:00AM EST  Avadel Pharmaceuticals to Present at Upcoming November 2020   GlobeNewswire Inc
Nov 9, 2020
07:17AM EST  Avadel Pharmaceuticals Q3 EPS $(0.20) Beats $(0.25) Estimate   Benzinga
07:00AM EST  -- NDAfor once-nightly FT218 is on track for FDA submission by end of December 2020 -- New market assessment dataidentifies a significant potential market expansion opportunity for once-nightly FT218beyondexisting twice-nightly sodium oxybate patients -- Management to host a conference call today at 8:30 a.m. ET   GlobeNewswire Inc
04:13AM EST  Earnings Scheduled For November 9, 2020   Benzinga
Oct 26, 2020
08:00AM EDT  Avadel Pharmaceuticals to Report Third Quarter 2020 Financial   GlobeNewswire Inc
Sep 17, 2020
08:27AM EDT  Avadel To Present At Oppenheimer Fall Healthcare Life Sciences & MedTech Summit Sept. 22   Benzinga
08:01AM EDT  Avadel Pharmaceuticals plc(Nasdaq: AVDL) a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate, today announced that its executive team will be presenting at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit taking place September 21 23, 2020.   GlobeNewswire Inc
Sep 14, 2020
09:20AM EDT  Avadel Pharmaceuticals Announces FT218 Leadership Transition; CMO Jordan Dubow Stepping Down   Benzinga
08:00AM EDT  -- Jordan Dubow, M.D. stepping down as CMO and will continue as a consultant to the Company through the FT218 NDA submission and review -- Seasoned industry veteran and Avadel Board member, Mark McCamish, M.D., Ph.D., to work with management and provide direct leadership of the FT218 program   GlobeNewswire Inc
Sep 11, 2020
04:36PM EDT  Avadel Pharmaceuticals plc(Nasdaq: AVDL) a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate, today announced that its executive team will be presenting at the H.C. Wainwright 22nd Annual Global Investment Conference taking place September 14 16, 2020.   GlobeNewswire Inc
Aug 10, 2020
11:06AM EDT  Avadel Pharmaceuticals shares are trading higher after the company reported better-than-expected Q2 EPS results. UPDATE: Shares have reversed since then.   Benzinga
08:35AM EDT  Recap: Avadel Pharmaceuticals Q2 Earnings   Benzinga
08:21AM EDT  Avadel Pharmaceuticals Q2 EPS $0.49 Beats $(0.10) Estimate   Benzinga
08:00AM EDT  Avadel Pharmaceuticals Reports Second Quarter 2020 Financial   GlobeNewswire Inc
04:10AM EDT  Earnings Scheduled For August 10, 2020   Benzinga
Jul 30, 2020
05:17PM EDT  Hearing Oppenheimer Initiated Coverage On Avadel Pharmaceuticals With Outperform Rating, $19 Price Target   Benzinga
Jul 27, 2020
08:01AM EDT  Avadel Pharmaceuticals plc (Nasdaq: AVDL) announced today that it will host a conference call and live webcast at 8:30 a.m. ET on Monday, August 10, 2020, to provide a corporate update and discuss the Company's financial results for the second quarter ended June 30, 2020.   GlobeNewswire Inc
Jul 21, 2020
09:37AM EDT  Benzinga's Top Upgrades, Downgrades For July 21, 2020   Benzinga
06:51AM EDT  SVB Leerink Initiates Coverage On Avadel Pharmaceuticals with Outperform Rating, Announces Price Target of $17   Benzinga
Jul 13, 2020
08:11AM EDT  Avadel Says First Patient Dosed In Open-Label Extension/Switch Study Of FT218   RTTNews
08:07AM EDT  Avadel Pharmaceuticals Announces First Patient Dosed In Open-Label Extension/Switch Study Of Investigation FT218 As Potential Treatment For Excessive Daytime Sleepiness, Cataplexy In Patients With Narcolepsy   Benzinga
08:02AM EDT  Avadel Pharmaceuticals Announces First Patient Dosed In Open-Label Extension/Switch Study Of Investigational Once-Nightly FT218 As A Potential Treatment For Excessive Daytime Sleepiness And Cataplexy In Patients With Narcolepsy   Benzinga
08:00AM EDT  -- Clinical study to enroll 250 patients from sites that participated in the REST-ON study -- Study to examine the long-term safety and maintenance of efficacy in patients, and evaluate dosing and preference for patients switching from twice-nightly sodium oxybate to once-nightly FT218   GlobeNewswire Inc


Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2025 ChartExchange LLC